HCV in 2018 | Jürgen Rockstroh, MD

International Workshop on Co-infection: HIV, Hepatitis, and Liver Disease 2018

Regulatory landscape for NASH | Veronica Miller

HEP DART 2017

Aramchol for NASH and beyond: From scientific rationale to clinical development | Carol Brosgart

HEP DART 2017

The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations | Manal El-Sayed, MD, PhD

HEP DART 2017

The Re-vival of Bile Acid Based Therapeutics for Children and Adults | Saul Karpen

HEP DART 2017

NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes | Arun Sanyal

HEP DART 2017

Looking back to move forward: designing next-gen RNAi for best results in HBV | Bruce Given

HEP DART 2017

HEV Update: Diagnostics and Management | Kenneth Sherman, MD, PhD

HEP DART 2017

Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination | Fabien Zoulim, MD, PhD

HEP DART 2017

Update on Merck’s HCV Program | Mike Robertson

HEP DART 2017

Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination | Tarik Asselah

HEP DART 2017

DAA Controversies: Do they Cause HBV Reactivation and/or HCC? | Jordan Feld, MD, MPH

HEP DART 2017

Management of HCV in Decompensated liver disease | Michael Manns

HEP DART 2017

Clinical Challenges in HCV infection | Mark Sulkowski, MD

HEP DART 2017

SB 9200: A novel RIG-I agonist for chronic hepatitis B | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

HEP DART 2017

Development of Immune Competent Small Animal Models for HBV | Helene Strick-Marchand

HEP DART 2017

Core Antibody: anti-HBc What is the Core of the Story? | Robert Gish, MD

HEP DART 2017

Endpoints and New Targets for Curing Hepatitis B | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

HEP DART 2017

Is Host Genome Integrated HBV Relevant? - The Con Perspective | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)

HEP DART 2017

Personalized Approaches to HBV Cure | Marion Peters, MD

HEP DART 2017

Immunology of HBV | Adam Gehring, PhD

HEP DART 2017

Short Duration DAA HCV Therapy: How Short Can We Go? | Shyam Kottilil, MD, PhD

HEP DART 2017

DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination | Jason Grebely

HEP DART 2017

Liver Disease in Chinese-perspective from a Hepatologist | George Lau, MBBS, MRCP, FHKCP, FHKAM, MD, FRCP

HEP DART 2017